Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Quick reference

Iboga and Ibogaine quick reference

A compact orientation to the plant, the alkaloid, the metabolite, evidence, safety, law, culture, and media records.

Core distinctions

Iboga
Tabernanthe iboga and related Central African cultural, ecological, conservation, and stewardship contexts.
Ibogaine
A psychoactive indole alkaloid studied for opioid withdrawal, substance use, TBI-related symptoms, and other neuropsychiatric questions, with serious safety and legal constraints.
Noribogaine
A metabolite and drug-development focus. FDA permission for an investigational study is not FDA approval and does not establish safety or effectiveness.
Analogs
18-MC, tabernanthalog, and related derivatives are tracked by molecule, sponsor, evidence type, and clinical status. They are not interchangeable with Iboga or Ibogaine.